PeptideStack
5.2kquestions
20kanswers
220users

clinical-trials

Page 23 of 32 · 745 questions tagged clinical-trials.

745 questions · sorted by votes · page 23 of 32

12 votes 5 answers10k views
What does STEP 8 tell me about hair thinning at the 1 mg dose?

Numbers first: STEP 8 · hair thinning · 1 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

50 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by felix_araya 6.8k · 2.0 years ago
12 votes 4 answers10k views
What is the reported incidence of reflux on oral semaglutide in PIONEER-1?

Details up front: reflux · oral semaglutide · PIONEER-1. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by halvard_ness 69k · 22 months ago
12 votes0 answers9.9k views
What does the mechanism of a GLP-1 receptor agonist predict that PIONEER-1 did not test?

Numbers first: a GLP-1 receptor agonist · PIONEER-1. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
asked by s_bhattacharya 31k · 2.1 years ago
12 votes 5 answers9.3k views
How comparable are semaglutide and mazdutide on the evidence available?

The particulars: semaglutide · mazdutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I can…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

237 questions
asked by assay_blank 45k · 7 months ago
12 votes 3 answers8.6k views
How comparable are orforglipron and retatrutide on the evidence available?

What I am working with: orforglipron · retatrutide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by ekaterina_volk 21k · 11 months ago
12 votes 2 answers8.3k views
Does the SURMOUNT-2 population resemble anyone asking about a GLP-1 receptor agonist here?

Setup, so nobody has to ask: SURMOUNT-2 · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by day_seven_trough 6.7k · 7 months ago
12 votes4 answers7.7k views
How comparable are a GLP-1 receptor agonist and survodutide on the evidence available?

Details up front: a GLP-1 receptor agonist · survodutide. I have used one of these for a while and I am considering switching, which requires a reason. What I care…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
asked by e_dziedzic 51k · 8 months ago
12 votes0 answers6.8k views
What did the placebo arm of SOUL report for dizziness?

What I have: SOUL · dizziness. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including the method…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
asked by harriet_lonsdale 35k · 10 months ago
12 votes0 answers6.4k views
What is the reported incidence of hair thinning on semaglutide in STEP 2?

Setup, so nobody has to ask: hair thinning · semaglutide · STEP 2. I would like help reading this properly rather than being told what conclusion to reach. I have the…

hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

50 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by eoin_mcgarry 18k · 10 months ago
12 votes 4 answers6.4k views
What did the placebo arm of TRIUMPH-1 report for constipation?

What I have: TRIUMPH-1 · constipation. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
asked by per_haugen 13k · 8 months ago
12 votes 5 answers6.3k views
What did the placebo arm of PIONEER-1 report for dizziness?

Setup, so nobody has to ask: PIONEER-1 · dizziness. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
asked by Dr_Ilse_Vandenberg 113k · 10 months ago
12 votes0 answers5.8k views
Why do two papers on REDEFINE-1 report different headline figures?

I have the full paper rather than the abstract, and the supplementary appendix. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by threadlock7 19k · 2.3 years ago
12 votes5 answers5.7k views
What does SURMOUNT-5 tell me about fatigue at the 15 mg dose?

What I am working with: SURMOUNT-5 · fatigue · 15 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
fatigue
fatigue

Tiredness on treatment: how much is energy deficit, how much is dehydration or electrolyte drift, how much is genuinely drug-attributable, and…

78 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by gel_pack_warm 13k · 10 months ago
12 votes0 answers2.7k views
What is the reported incidence of reflux on semaglutide in STEP 1?

The particulars: reflux · semaglutide · STEP 1. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by bounty_hunter_q 15k · 9 months ago
11 votes 5 answers27k views
What did the placebo arm of REDEFINE-1 report for fatigue?

Conditions: REDEFINE-1 · fatigue. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
fatigue
fatigue

Tiredness on treatment: how much is energy deficit, how much is dehydration or electrolyte drift, how much is genuinely drug-attributable, and…

78 questions
asked by swirl_dont_shake 10k · 2.4 years ago
11 votes 5 answers26k views
What did the placebo arm of SURMOUNT-1 report for constipation?

The particulars: SURMOUNT-1 · constipation. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
asked by dermot_kiely 12k · 17 months ago
11 votes 3 answers25k views
How comparable are retatrutide and semaglutide on the evidence available?

The particulars: retatrutide · semaglutide. Both of these get recommended confidently by different people, which suggests neither is obviously right. My constraints…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by swab_stopper 8.8k · 22 months ago
11 votes 5 answers21k views
What does SOUL tell me about reflux at the 14 mg dose?

What I am working with: SOUL · reflux · 14 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by juan_esquivel 14k · 14 months ago
11 votes 5 answers20k views
What does the mechanism of oral semaglutide predict that PIONEER-1 did not test?

What I am working with: oral semaglutide · PIONEER-1. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious. My…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by Dr_Wren_Halliday 19k · 23 months ago
11 votes 5 answers19k views
Is there any published stability data for retatrutide at minus 20 °C?

What I am working with: retatrutide · minus 20 °C. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by rania_haddad 13k · 20 months ago
11 votes 5 answers16k views
What did the placebo arm of SUSTAIN-6 report for nausea?

The particulars: SUSTAIN-6 · nausea. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
asked by amara_nwachukwu 20k · 11 months ago
11 votes 5 answers15k views
What does SURMOUNT-1 report at the 15 mg dose level?

Conditions: SURMOUNT-1 · 15 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which I…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by coring_risk 27k · 2.4 years ago
11 votes 5 answers14k views
What did the placebo arm of SURMOUNT-4 report for reflux?

What I am working with: SURMOUNT-4 · reflux. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by marcus_thorbjorn 9.4k · 13 months ago
11 votes 5 answers13k views
What is the reported incidence of constipation on semaglutide in FLOW?

Setup, so nobody has to ask: constipation · semaglutide · FLOW. I have read the primary source rather than the summary, which has left me with more questions. I…

constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by rhian_prydderch 23k · 2.2 years ago